

Immune Thrombocytopenia Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest Approvals by DelveInsight

Immune Thrombocytopenia companies are HanAll Biopharma, Immunovant, Momenta Pharmaceuticals, Hutchison MediPharma, Cour Pharmaceutical Development, and others.

LAS VEGAS, NEVADA, UNITED STATES, June 27, 2024 /EINPresswire.com/ --

DelveInsight's "Immune

Thrombocytopenia Market Insights, Epidemiology, and Market Forecast-2032" report offers an in-depth

understanding of the Immune

Thrombocytopenia, historical and forecasted epidemiology as well as the Immune

Thrombocytopenia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Immune Thrombocytopenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Immune Thrombocytopenia Market Forecast](#)

Some of the key facts of the Immune Thrombocytopenia Market Report:

The Immune Thrombocytopenia market size is anticipated to grow with a significant CAGR during the study period (2019-2032).


As per DelveInsight analysis, the immune thrombocytopenia market size in the 7MM was approximately USD 3,100 million in 2021.

According to the assessment done by DelveInsight, the estimated total immune thrombocytopenia prevalent cases in the 7MM were approximately 184K in 2021.

In June 2022, Sanofi presented the efficacy and adverse events data from a phase I/II trial in Idiopathic thrombocytopenic purpura at the 27th Congress of the European Haematology Association (EHA-2022).

In April 2022, Biotest submitted a marketing authorization application for IgG Next Generation in Germany.

Key Immune Thrombocytopenia Companies: UCB Biopharma, Sanofi, Principia Biopharma,



Argenx, Millennium Pharmaceuticals, Takeda, Biotest, GC Pharma, UCB, HanAll Biopharma, Immunovant, Momenta Pharmaceuticals, Hutchison MediPharma, Cour Pharmaceutical Development, and others

Key Immune Thrombocytopenia Therapies: Rilzabrutinib (PRN-1008), Efgartigimod (ARGX-113), BIVV020, TAK-079, BT-595, GC5101B (GC5107A, IV-Globulin SN Inj. 10%), Rozanolixizumab, and others

The Immune Thrombocytopenia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Immune Thrombocytopenia pipeline products will significantly revolutionize the Immune Thrombocytopenia market dynamics.

Immune Thrombocytopenia Overview

Immune thrombocytopenia (ITP), also referred to as immune thrombocytopenic purpura or idiopathic thrombocytopenic purpura, is an autoimmune disorder where the body's immune system attacks and rapidly destroys its own platelets. ITP is defined as any immune-mediated decrease in platelet count.

Primary ITP, which accounts for about 80% of cases, occurs without an underlying secondary disease. In contrast, secondary ITP can be triggered by various factors including systemic lupus erythematosus (SLE), certain medications, Hepatitis C, human immunodeficiency virus (HIV), Helicobacter pylori infection, Chronic Lymphocytic Leukemia (CLL), other lymphoproliferative disorders, antiphospholipid syndrome, vaccinations (particularly Measles/Mumps/Rubella [MMR]), Common Variable Immunodeficiency Disease (CVID), as well as other viral infections, post-transfusion reactions, and Evans syndrome. These secondary factors contribute to approximately 20% of ITP cases.

Immune Thrombocytopenia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

DelveInsight estimates that there were approximately 184K prevalent cases of immune thrombocytopenia in the 7MM in 2021.

As per the analysis, the total diagnosed prevalent cases in the 7MM was estimated to be approximately 150K in 2021.

Immune Thrombocytopenia Epidemiology Segmentation:

The Immune Thrombocytopenia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Immune Thrombocytopenia

Prevalent Cases of Immune Thrombocytopenia by severity

Gender-specific Prevalence of Immune Thrombocytopenia

Diagnosed Cases of Episodic and Chronic Immune Thrombocytopenia

Download the report to understand which factors are driving Immune Thrombocytopenia epidemiology trends @ [Immune Thrombocytopenia Epidemiology Forecast](#)

Immune Thrombocytopenia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Immune Thrombocytopenia market or expected to get launched during the study period.

The analysis covers Immune Thrombocytopenia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Immune Thrombocytopenia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Immune Thrombocytopenia Therapies and Key Companies

Rilzabrutinib (PRN-1008): Sanofi/Principia Biopharma

Efgartigimod (ARGX-113): Argenx

BIVV020: Sanofi

TAK-079: Millennium Pharmaceuticals/Takeda

BT-595: Biotest

GC5101B (GC5107A, IV-Globulin SN Inj. 10%): GC Pharma

Rozanolixizumab: UCB Biopharma

Immune Thrombocytopenia Treatment Market

The primary goal in treating immune thrombocytopenia is to achieve a platelet count sufficient to prevent significant bleeding rather than striving for normal platelet levels. Treatment approaches for immune thrombocytopenia vary widely, and international guidelines recommend several first- and second-line options, including medications not yet approved in the EU specifically for this condition.

In June 2019, the US Food and Drug Administration (FDA) approved avatrombopag (DOPTelet; Dova Pharmaceuticals) for managing thrombocytopenia in adults with chronic ITP who did not

respond adequately to prior treatments. Avatrombopag had previously received FDA approval in May 2018 for treating thrombocytopenia in adults with chronic liver disease scheduled for medical or dental procedures, marking it as the first drug to be approved for this indication.

Immunosuppressants such as azathioprine (IMURAN), cyclosporine (NEORAL, Sandimmune), cyclophosphamide (CYTOXAN), and mycophenolate (CELLCEPT) have been used individually with varying efficacy, although their use is limited due to associated drug toxicity and safety concerns. Emerging research indicates that combination chemotherapy could potentially offer improved effectiveness and reduced adverse effects in treating chronic refractory ITP.

In Japan, TAKECAB and NEXIUM capsules are approved for eradicating *H. pylori* in ITP patients, with TAKECAB receiving approval in 2014 and NEXIUM capsules in 2011. Future prospective trials are essential to refine treatment strategies and enhance overall patient outcomes.

Immune Thrombocytopenia Market Dynamics

The immune thrombocytopenia market is poised for transformation in the upcoming period, driven by the expected launch of new therapies. A variety of pipeline treatments are currently under development for managing ITP patients, and the introduction of these new products, alongside enhancements to existing therapies, will fuel market expansion.

Corticosteroid medications, known for their versatility and cost-effectiveness, are anticipated to maintain a significant market share in developed countries. Additionally, the increasing adoption of TPO-RA as a second-line treatment will further stimulate growth in the immune thrombocytopenia market. The global rise in ITP prevalence and heightened disease awareness across the Seven Major Markets (7MM) will also contribute to market expansion throughout the forecast period.

However, several factors may hinder the growth of the immune thrombocytopenia market. The superior efficacy of alternative treatments such as platelet transfusions and surgical interventions compared to available drugs is expected to pose challenges. Furthermore, a decline in pediatric ITP treatment rates and a lack of late-stage pipeline activities could result in a stagnant treatment landscape.

Moreover, the side effects associated with current ITP medications may prompt patients to seek alternative therapies. Additionally, the anticipated patent expiration of key branded TPO-RA drugs by the end of 2022 will reduce the cost of second-line therapy, potentially impacting market growth. The introduction of generics and biosimilars for ITP treatment is also projected to diminish sales in the immune thrombocytopenia market in the near future.

Scope of the Immune Thrombocytopenia Market Report

Study Period: 2019–2032

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom),

and Japan]

Key Immune Thrombocytopenia Companies: UCB Biopharma, Sanofi, Principia Biopharma, Argenx, Millennium Pharmaceuticals, Takeda, Biotest, GC Pharma, UCB, HanAll Biopharma, Immunovant, Momenta Pharmaceuticals, Hutchison MediPharma, Cour Pharmaceutical Development, and others

Key Immune Thrombocytopenia Therapies: Rilzabrutinib (PRN-1008), Efgartigimod (ARGX-113), BIVV020, TAK-079, BT-595, GC5101B (GC5107A, IV-Globulin SN Inj. 10%), Rozanolixizumab, and others

Immune Thrombocytopenia Therapeutic Assessment: Immune Thrombocytopenia current marketed and Immune Thrombocytopenia emerging therapies

Immune Thrombocytopenia Market Dynamics: Immune Thrombocytopenia market drivers and Immune Thrombocytopenia market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Immune Thrombocytopenia Unmet Needs, KOL's views, Analyst's views, Immune Thrombocytopenia Market Access and Reimbursement

To know more about Immune Thrombocytopenia companies working in the treatment market, visit @ [Immune Thrombocytopenia Clinical Trials and Therapeutic Assessment](#)

Table of Contents

1. Immune Thrombocytopenia Market Report Introduction
 2. Executive Summary for Immune Thrombocytopenia
 3. SWOT analysis of Immune Thrombocytopenia
 4. Immune Thrombocytopenia Patient Share (%) Overview at a Glance
 5. Immune Thrombocytopenia Market Overview at a Glance
 6. Immune Thrombocytopenia Disease Background and Overview
 7. Immune Thrombocytopenia Epidemiology and Patient Population
 8. Country-Specific Patient Population of Immune Thrombocytopenia
 9. Immune Thrombocytopenia Current Treatment and Medical Practices
 10. Immune Thrombocytopenia Unmet Needs
 11. Immune Thrombocytopenia Emerging Therapies
 12. Immune Thrombocytopenia Market Outlook
 13. Country-Wise Immune Thrombocytopenia Market Analysis (2019–2032)
 14. Immune Thrombocytopenia Market Access and Reimbursement of Therapies
 15. Immune Thrombocytopenia Market Drivers
 16. Immune Thrombocytopenia Market Barriers
 17. Immune Thrombocytopenia Appendix
 18. Immune Thrombocytopenia Report Methodology
 19. DelveInsight Capabilities
 20. Disclaimer
 21. About DelveInsight
- Related Reports:

Immune Thrombocytopenia Pipeline

"Immune Thrombocytopenia Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Immune Thrombocytopenia market. A detailed picture of the Immune Thrombocytopenia pipeline landscape is provided, which includes the disease overview and Immune Thrombocytopenia treatment guidelines.

Immune Thrombocytopenia Epidemiology

DelveInsight's 'Immune Thrombocytopenia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Immune Thrombocytopenia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Kritika Rehani

DelveInsight Business Research LLP

+1 469-945-7679

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/723354828>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire,

Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.